 with the development of coronary heart disease: six years’ follow-up experience in the Framingham
study. Am J Public Health Nations Health 1959;49:1349-56.
14. Smith SC Jr, Milani RV, Arnett DK, Crouse JR 3rd, McDermott MM,
Ridker PM, et al. Atherosclerotic Vascular Disease Conference: Writing
Group II: risk factors. Circulation 2004;109:2613-6.
15. Murabito JM, D’Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk proﬁle from The Framingham Heart Study.
Circulation 1997;96:44-9.
16. Zelis R, Mason DT, Braunwald E, Levy RI. Effects of hyperlipoproteinemias and their treatment on the peripheral circulation.
J Clin Invest 1970;49:1007-15.
17. Couch NP. On the arterial consequences of smoking. J Vasc Surg
1986;3:807-12.
18. Al-Delaimy WK, Merchant AT, Rimm EB, Willett WC,
Stampfer MJ, Hu FB. Effect of type 2 diabetes and its duration on
the risk of peripheral arterial disease among men. Am J Med
2004;116:236-40.
19. Kullo IJ, Bailey KR, Kardia SL, Mosley TH Jr, Boerwinkle E,
Turner ST. Ethnic differences in peripheral arterial disease in the
NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA)
study. Vasc Med 2003;8:237-42.
20. O’Hare AM, Vittinghoff E, Hsia J, Shlipak MG. Renal insufﬁciency
and the risk of lower extremity peripheral arterial disease: results from
the Heart and Estrogen/Progestin Replacement Study (HERS). J Am
Soc Nephrol 2004;15:1046-51.
21. Graham IM,